Treatment for Lung Cancer
Dear Bradford Teaching Hospitals NHS Foundation Trust,
The following question is being requested on behalf of Novartis. The purpose of these questions is to understand the variability of treatment within your trust and in context to
the rest of the country.
Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
• Afatinib
• Alectinib
• Atezolizumab monotherapy
• Atezolizumab in combination
• Bevacizumab
• Brigatinib
• Capmatenib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Docetaxel monotherapy
• Durvalumab
• Erlotinib
• Gefitinib
• Gemcitabine
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Paclitaxel
• Pembrolizumab monotherapy
• Pembrolizumab in combination
• Pemetrexed with Carboplatin/Cisplatin
• Tepotinib
• Vinorelbine with Cisplatin/Carboplatin
• Any other SACT
• Palliative care only
Thank you for taking the time to answer this question and I look forward to hearing from you.
Yours faithfully,
Ben Holdsworth
Dear Ben
Thank you for your recent Freedom of Information request. Under the terms of the Freedom of Information Act we will endeavour to respond to this request promptly within 20 working days and are now investigating the nature of the request, the quantity of information requested and whether we hold the information requested.
There are a number of exemptions which the Act permits with respect to disclosure of information. The information will be assessed for these exemptions prior to disclosure and we will advise you if we are unable to provide the information requested.
If there is a cost involved in collecting the information then we will suspend the period for response until such time as we receive your payment. We will advise you of any such costs.
Please send any further correspondence to [email address].
Kind regards,
Julie Hill
Dear Ben
Please find attached our response to your request for information.
Kind regards
Julie Hill
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now